Last reviewed · How we verify
rhuGM-CSF
At a glance
| Generic name | rhuGM-CSF |
|---|---|
| Also known as | Leukine®, Leukine, Sargramostim |
| Sponsor | Bionor Immuno AS |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer (PHASE1)
- Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer (PHASE2)
- Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (PHASE2)
- AST-021p Study in Advanced Solid Tumors (PHASE1)
- Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (PHASE2)
- A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma (PHASE1)
- Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (PHASE1, PHASE2)
- Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhuGM-CSF CI brief — competitive landscape report
- rhuGM-CSF updates RSS · CI watch RSS
- Bionor Immuno AS portfolio CI